Effect of IMOD™ on the inflammatory process after acute ischemic stroke: a randomized clinical trial

[1]  H. Sadeghi-Bazargani,et al.  Effect of IMOD™ on the inflammatory process after acute ischemic stroke: a randomized clinical trial , 2013, DARU Journal of Pharmaceutical Sciences.

[2]  Farzaneh Vafaee,et al.  Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats★ , 2012, Neural regeneration research.

[3]  M. Abdollahi,et al.  Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategy , 2012, DARU Journal of Pharmaceutical Sciences.

[4]  A. Tuttolomondo,et al.  Inflammation in ischemic stroke subtypes. , 2012, Current pharmaceutical design.

[5]  P. McColgan,et al.  Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. , 2012, British journal of clinical pharmacology.

[6]  B. McColl,et al.  Delayed Administration of Interleukin-1 Receptor Antagonist Reduces Ischemic Brain Damage and Inflammation in Comorbid Rats , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  K. Lambertsen,et al.  Inflammatory Cytokines in Experimental and Human Stroke , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  P. Rana,et al.  C-reactive protein and early mortality in acute ischemic stroke. , 2012, Kathmandu University medical journal.

[9]  A. Munshi,et al.  C-Reactive Protein and Nitric Oxide Levels in Ischemic Stroke and Its Subtypes: Correlation with Clinical Outcome , 2012, Inflammation.

[10]  H. Kamel,et al.  Brain-immune interactions and ischemic stroke: clinical implications. , 2012, Archives of neurology.

[11]  C. Pasquali,et al.  Neuroprotection by inhibiting the c-Jun N-terminal kinase pathway after cerebral ischemia occurs independently of interleukin-6 and keratinocyte-derived chemokine (KC/CXCL1) secretion , 2012, Journal of Neuroinflammation.

[12]  M. Mohraz,et al.  Safety and efficacy of Setarud (IMOD TM ) among people living with HIV/AIDS: a review. , 2012, Recent patents on anti-infective drug discovery.

[13]  K. Kovács,et al.  Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood- brain barrier damage and brain oedema independently of infarct size , 2011, Journal of Neuroinflammation.

[14]  N. Rothwell,et al.  Interleukin-1 and Stroke: Biomarker, Harbinger of Damage, and Therapeutic Target , 2011, Cerebrovascular Diseases.

[15]  M. Yousefi,et al.  In vitro immunoinhibitory effects of Setarud on human B lymphocyte , 2011 .

[16]  D. B. Dock-Nascimento,et al.  Early enteral nutrition with whey protein or casein in elderly patients with acute ischemic stroke: a double-blind randomized trial. , 2011, Nutrition.

[17]  E. Park,et al.  Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke , 2010, Journal of Neuroimmunology.

[18]  M. Abdollahi,et al.  Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes , 2010, Archives of medical science : AMS.

[19]  M. Abdollahi,et al.  Efficacy of Setarud (IMod), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. , 2010, Indian journal of biochemistry & biophysics.

[20]  J. Brøgger,et al.  Admission C – reactive protein after acute ischemic stroke is associated with stroke severity and mortality: The 'Bergen stroke study' , 2009, BMC neurology.

[21]  T. Sobrino,et al.  Inflammatory and Neuroimmunomodulatory Changes in Acute Cerebral Ischemia , 2009, Cerebrovascular Diseases.

[22]  B. McColl,et al.  Systemic infection, inflammation and acute ischemic stroke , 2009, Neuroscience.

[23]  J. Jordán,et al.  Inflammation as therapeutic objective in stroke. , 2008, Current pharmaceutical design.

[24]  C. Molina,et al.  Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial , 2007, European journal of neurology.

[25]  S. Akira,et al.  Identification of a key pathway required for the sterile inflammatory response triggered by dying cells , 2007, Nature Medicine.

[26]  Vinychuk Sm,et al.  [Effect of flogensim in the treatment of postischemic inflammation (according to results of using interleukin-6 in patients with acute brain infarction)]. , 2007 .

[27]  Qing Wang,et al.  The inflammatory response in stroke , 2007, Journal of Neuroimmunology.

[28]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[29]  P. Ogunro,et al.  Plasma selenium concentration and glutathione peroxidase activity in HIV-1/AIDS infected patients: a correlation with the disease progression. , 2006, The Nigerian postgraduate medical journal.

[30]  J. Edelberg.  Vascular pathology and repair in the aging heart: alterations in inflammatory mediators , 2004 .

[31]  D. Anthony,et al.  Anti-inflammatory modulators in stroke , 2004 .

[32]  Süheyla Karataş Düğenci,et al.  Some medicinal plants as immunostimulant for fish. , 2003, Journal of ethnopharmacology.

[33]  A. Paetau,et al.  Evolution of Cerebral Tumor Necrosis Factor-&agr; Production During Human Ischemic Stroke , 2001, Stroke.

[34]  M. Abdollahi,et al.  Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function , 2001, Human & experimental toxicology.

[35]  M. Rayman,et al.  The importance of selenium to human health , 2000, The Lancet.

[36]  Michael Schroeter,et al.  Inflammation and glial responses in ischemic brain lesions , 1998, Progress in Neurobiology.

[37]  M. Recio,et al.  Anti‐inflammatory Effects of South American Tanacetum vulgare , 1998, The Journal of pharmacy and pharmacology.

[38]  F. Barone,et al.  The Role of Cytokines in the Neuropathology of Stroke and Neurotrauma , 1998, Neuroimmunomodulation.

[39]  Look,et al.  Sodium selenite and N‐acetylcysteine in antiretroviral‐naive HIV‐1‐infected patients: a randomized, controlled pilot study , 1998, European journal of clinical investigation.

[40]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[41]  J. Eikelboom,et al.  Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial , 2011, Journal of Thrombosis and Thrombolysis.

[42]  M. Abdollahi,et al.  Examination of Setarud (IMOD™) in the management of patients with severe sepsis , 2010, Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.

[43]  M. Khoshayand,et al.  Identification of enhanced cytokine generation following sepsis. Dream of magic bullet for mortality prediction and therapeutic evaluation , 2010, Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.

[44]  Heshmat Ramin,et al.  PRECLINICAL AND PHASE 1 CLINICAL SAFETY OF SETARUD (IMODTM), A NOVEL IMMUNOMODULATOR , 2009 .

[45]  M. Abdollahi,et al.  Studies on potential mutagenic and genotoxic activity of Setarud , 2008 .

[46]  S. M. Vinychuk,et al.  [Effect of flogensim in the treatment of postischemic inflammation (according to results of using interleukin-6 in patients with acute brain infarction)]. , 2007, Likars'ka sprava.